Skip to main content

Malaria positivity following a single oral dose of azithromycin among children in Burkina Faso: a randomized controlled trial



Azithromycin is a broad-spectrum antibiotic that has moderate antimalarial activity and has been shown to reduce all-cause mortality when biannually administered to children under five in high mortality settings in sub-Saharan Africa. One potential mechanism for this observed reduction in mortality is via a reduction in malaria transmission.


We evaluated whether a single oral dose of azithromycin reduces malaria positivity by rapid diagnostic test (RDT). We conducted an individually randomized placebo-controlled trial in Burkina Faso during the high malaria transmission season in August 2020. Children aged 8 days to 59 months old were randomized to a single oral dose of azithromycin (20 mg/kg) or matching placebo. At baseline and 14 days following treatment, we administered a rapid diagnostic test (RDT) to detect Plasmodium falciparum and measured tympanic temperature for all children. Caregiver-reported adverse events and clinic visits were recorded at the day 14 visit.


We enrolled 449 children with 221 randomized to azithromycin and 228 to placebo. The median age was 32 months and 48% were female. A total of 8% of children had a positive RDT for malaria at baseline and 11% had a fever (tympanic temperature ≥ 37.5 °C). In the azithromycin arm, 8% of children had a positive RDT for malaria at 14 days compared to 7% in the placebo arm (P = 0.65). Fifteen percent of children in the azithromycin arm had a fever ≥ 37.5 °C compared to 21% in the placebo arm (P = 0.12). Caregivers of children in the azithromycin group had lower odds of reporting fever as an adverse event compared to children in the placebo group (OR 0.41, 95% CI 0.18–0.96, P = 0.04). Caregiver-reported clinic visits were uncommon, and there were no observed differences between arms (P = 0.32).


We did not find evidence that a single oral dose of azithromycin reduced malaria positivity during the high transmission season. Caregiver-reported fever occurred less often in children receiving azithromycin compared to placebo, indicating that azithromycin may have some effect on non-malarial infections.

Trial registration NCT04315272, registered 19/03/2020

Peer Review reports


Children under 5 are the most vulnerable age group affected by malaria, accounting for 67% of all malaria deaths in 2019 [1]. The malaria burden is often greatest during the first few years of life, before natural immunity is acquired [2]. Interventions such as seasonal malaria chemoprevention (SMC) have reduced deaths from severe malaria, but growing resistance to first line antimalarial drugs threatens to impede progress [3, 4]. Azithromycin is a macrolide with modest anti-malarial properties that has been shown to have a negative impact on the asexual stages of the Plasmodium falciparum parasite [5]. While azithromycin is not widely used for malaria control, mass biannual azithromycin distribution has been shown to reduce all-cause child mortality and malaria parasitemia among preschool aged children in some settings [6,7,8].

Burkina Faso is hyperendemic for malaria with more than 20 million people at risk [9]. The Burkinabè Ministry of Health estimates that 66% of all deaths in children under 5 were attributable to malaria in 2018 [10]. Here we investigate changes in malaria positivity determined by rapid diagnostic test (RDT) among Burkinabè children 8 days to 59 months old who were individually randomized to receive a single dose of azithromycin or placebo. We hypothesized that children receiving azithromycin would have lower RDT positivity after a 14-day period compared to those receiving placebo.


Study overview

This study was a placebo-controlled individually randomized trial evaluating a single oral dose of azithromycin (20 mg/kg) compared to placebo for malaria among children under 5 ( NCT04315272, registered 19/03/2020). We conducted assessments at baseline and 14 days following enrollment. We also collected stool samples from the participants over a 6-month period, but these results will be reported separately. The trial was approved by the Comité National d’Ethique pour la Recherche (National Ethics Committee of Burkina Faso) in Ouagadougou, Burkina Faso and the Institutional Review Board at the University of California, San Francisco. Written informed consent was obtained from the caregiver prior to enrollment.

Study setting

The trial was conducted in Nouna town in northwestern Burkina Faso, which is approximately 300 km from the capital city Ouagadougou. Nouna is the capital of Kossi province with an estimated 25,000 inhabitants of various ethnic groups (Fig. 1) [11]. The population is peri-urban and consists almost exclusively of subsistence farmers. The climate is sub-Saharan, with an estimated mean annual rainfall of 796 mm [12]. The Nouna Health Research Center (CRSN) is a partner of the Ministry of Health and implements the Nouna Health and Demographic Surveillance System (HDSS). The HDSS encompasses the entire Nouna district including approximately 59 villages and 107,000 inhabitants. The HDSS was established in 1992 for the collection of longitudinal data to assess natality, mortality, and migration [12,13,14].

Fig. 1
figure 1

Map of the study area

Children were enrolled in mid-August 2020 at the Nouna District Hospital. The primary endpoint occurred 2 weeks following enrollment in September 2020. In this setting malaria transmission is highly seasonal and typically peaks from July through October during the rainy season [15]. Seasonal malaria chemoprophylaxis was administered concurrently to children aged 3–59 months on a monthly basis from July to October in Nouna town. The predominant malaria vector in the region is the Anopheles gambiae complex, and the Anopheles coluzzi species is most commonly found in Nouna [16]. P. falciparum is the primary malaria species infecting humans in the region [17].

Recruitment and eligibility

Mobilizers sensitized the community by visiting households with children under 5 based on the most recent census conducted by the Nouna Health and Demographic Surveillance Site (HDSS) [14]. Study staff informed caregivers about the study, and interested participants were encouraged to present to the Nouna District Hospital to be assessed for eligibility. Children meeting the following criteria were eligible for the study: age between 8 days and 59 months old, primary residence within Nouna town, available for the next 6-month period, no known allergy to macrolides, and able to orally feed (to swallow the study medication).

Baseline assessment

At baseline, study staff conducted a survey with the caregiver. Questions included breastfeeding status, maternal age, the mother’s level of education, literacy, and gravidity. The study staff member utilized a custom mobile application to input all data into a handheld tablet (Dimagi, Inc., CommCare, 2020).

Malaria assessment

An OnSite Pf/Pan antigen rapid test (CTK Biotech Inc, USA) was used to detect Plasmodium falciparum among all participants regardless of presence of fever at baseline and 14 days following treatment. Study staff measured tympanic temperature for all children at both study visits using the Braun Thermoscan 7 Digital Ear thermometer (Kaz, Inc., USA). Fever was defined as tympanic temperature ≥ 37.5 °C. Febrile children and those with a positive malaria RDT were referred for care.


Enrolled participants were randomized to receive a single oral dose of azithromycin (20 mg/kg) or equivalent volume of matching placebo. The placebo was identical to the azithromycin in appearance and taste. Dosage was determined by height stick approximation if the child was able to stand or by weight if the child was under 12 months of age and/or unable to stand [18]. The medication was administered as an oral suspension with a plastic dosing cup or syringe. All treatments were directly observed by the study team and recorded in the electronic mobile application.


The randomization sequence was generated by the study statistician without blocking or stratifying in R. Unique participant identification numbers were created which were associated with the randomization assignment and uploaded into the electronic data capture platform. The trial was double masked and all field team members and participants were masked. The allocation concealment mechanism was a combination of the unique participant IDs and matching drug labels. The drug was labeled with 1 of 8 different letters to avoid the possibility of unmasking. After a participant ID was assigned to the child, the field team member scanned the ID into the electronic mobile application which then informed the team member which letter to treat the child with.

Follow-up assessment

Caregivers presented to the hospital 14 days after the baseline visit. A brief interview was conducted with the caregiver regarding any adverse events experienced by the child since treatment including abdominal pain, diarrhea, vomiting, constipation, or skin rash. These adverse events were specifically asked based on findings from previous pediatric azithromycin trials [19,20,21]. Caregivers also reported if healthcare was sought for the child since treatment and the diagnosis (e.g. diarrhea, pneumonia, malaria).


The primary outcome for this trial was Shannon’s and Simpson’s diversity index of the gut microbiome at 6 months and will be reported separately. Secondary outcomes included malaria status at 14 days post enrollment determined by RDT, clinical malaria at 14 days post enrollment defined by a positive RDT and tympanic temperature ≥ 37.5 °C, caregiver-reported adverse events, and clinic visits.

Sample size

The sample size was based on the primary outcome of the trial which was Shannon’s and Simpson’s diversity index of the gut microbiome. For the malaria outcome, we assumed 80% power to detect a significant effect with a sample size of 225 per arm, no loss to follow-up, and RDT positivity prevalence in the control group of 10%. Given these assumptions, the trial was powered to detect an absolute difference of 6.6%.

Statistical methods

Descriptive baseline characteristics were summarized with proportions for categorical variables and medians and interquartile ranges (IQR) for continuous variables. The proportion of participants with a fever (defined as tympanic temperature ≥ 37.5 °C) at the time of the follow-up visit was calculated. We also calculated the proportion of children with a positive malaria RDT at the 14-day visit. Caregiver-reported health center visits were classified by arm and reason for the visit. Lastly, we calculated the proportion of children experiencing any adverse event as reported by their caregiver by study arm as well as each individual adverse event. Odds ratios (OR) and 95% confidence intervals (CI) were computed for each outcome using an unadjusted logistic regression model with the randomized treatment arm assigned as the predictor. Because RDTs can remain positive for several weeks even if there is no longer an active infection, we restricted the 14-day RDT model to children who were RDT negative at baseline as a sensitivity analysis. All analyses were intention-to-treat, where all randomized children were included regardless if they received their randomized assignment or not. Analyses were performed in Stata version 15.1 (StataCorp, College Station, TX).


A total of 449 children were enrolled in the trial with 221 in the azithromycin arm and 228 in the placebo arm (Fig. 2). Baseline characteristics were balanced between groups (Table 1). The median age was 32 months for the azithromycin group and 32.5 for the placebo group. Three participants were under 1 month of age with the youngest being 32 days old. In both groups, 48% were female. Among the 449 children enrolled, 446 (99%) received their study treatment. At baseline, 10% of children in the azithromycin group and 7% in the placebo group were RDT positive. Two percent of participants in the azithromycin arm and 0.4% of participants in the placebo arm had a positive malaria RDT plus fever. Two children (1 per arm) were lost to follow-up (Fig. 2).

Fig. 2
figure 2

CONSORT flow diagram of study participants

Table 1 Baseline characteristics by treatment group

We did not find any evidence of a difference between the azithromycin and placebo arms for malaria or clinical outcomes at 14 days (Table 2). Malaria RDT positivity remained similar in the placebo group (7%) and azithromycin group (8%) (OR 1.18 for azithromycin vs placebo, 95% CI 0.58 to 2.37, P = 0.65). At the 14-day follow-up, 33 children (15%) in the azithromycin group had a tympanic temperature ≥ 37.5 °C versus 47 children (21%) in the placebo group. Three percent of children in both arms had a positive malaria RDT plus fever at 14 days. There were 15 participants with a negative RDT at baseline which then became positive at 14-days (3% azithromycin; 4% placebo, OR: 0.90, 95% CI 0.32 to 2.45, P = 0.85). We did not find evidence of an effect of azithromycin on RDT positivity without fever (Table 2).

Table 2 Malaria and clinical outcomes at 14 days by treatment group

Caregivers of 3% of participants reported their child had a health center visit by the 14-day visit with no evidence of a difference between arms (2% azithromycin; 4% placebo, OR: 0.56, CI 0.19 to 1.71, P = 0.31). Diarrhea was the most common reason for a health center visit across both arms (OR 1.03 for azithromycin vs placebo, 95% CI 00.21 to 5.17, P = 0.97).

The results of the sensitivity analysis did not qualitatively change the results as we found no evidence of an effect of azithromycin on 14-day malaria RDT positivity in children with a negative RDT at baseline (OR 0.95 for azithromycin vs placebo, 95% CI 0.34 to 2.68, P = 0.93).

Overall, 12% of caregivers reported that their child experienced at least a single adverse event in the 14-day period after treatment with 20 in the azithromycin arm (9%) and 32 in the placebo arm (14%) (Table 3). Caregivers of children in the azithromycin arm had lower odds of reporting fever as an adverse event compared to children in the placebo group (OR 0.41, 95% CI 0.18 to 0.96, P = 0.04). Diarrhea was the most commonly reported adverse event and there was no significant difference between study arms (5% azithromycin; 8% placebo; OR 0.61, 95% CI 0.28 to 1.33, P = 0.21). We did not find evidence of a difference in any other adverse events.

Table 3 Adverse events at 14 days by treatment group


We did not find evidence that a single oral dose of azithromycin reduces malaria positivity within a 14-day period after treatment. One consideration is the coinciding seasonal malaria chemoprophylaxis (SMC) that was administered at the same time as the trial within the Nouna community. SMC distributions with sulfadoxine–pyrimethamine (SP) and amodiaquine (AQ) to children aged 3–59 months occurred monthly from July 13th–16th, August 12th–15th, September 11th–14th, and October 10th–13th. A trial in Burkina Faso and Mali found SMC + AZ provided additional protection from malaria, but this effect was limited to the first 2 weeks post-administration [22]. Concomitant SMC distribution during the trial period may explain the lower than expected malaria prevalence we observed (8% RDT positivity at baseline and follow-up) [23,24,25,26].

Community-level distribution of AZ could be more effective for malaria control compared to individual-level distribution as several community based trials have demonstrated that mass AZ distribution reduces malaria parasitemia [8, 24, 27, 28]. For instance, a subset of villages in the MORDOR Niger trial reported that communities receiving azithromycin had half the odds of malaria parasitemia compared to communities treated with placebo [7, 8]. Trachoma trials have also documented a reduction in malaria parasitemia following mass azithromycin distribution, although the evidence is mixed [24, 26, 28,29,30,31]. Additionally, distributing AZ to communities may provide limited vector control as some studies suggest azithromycin decreases mosquito lifespan when ingested [32]. While individual-level interventions may have some impact on malaria transmission, it may be difficult to show a difference if the rate of reinfection is high, as during the peak transmission season. The present study did not collect serological data which could measure force of infection or measure the entomological inoculation rate. Community-level AZ interventions may have a greater impact on malaria transmission compared to individual-level interventions, but more research is needed.

We observed a lower probability of caregiver-reported fever in the azithromycin group compared to the placebo group, suggesting that azithromycin may have an effect on non-malaria fevers. Gastroenteritis and pneumonia were reduced 30% and 34% respectively in a West African azithromycin trial, suggesting AZ may lower other fever-inducing infections commonly found in sub Saharan Africa [22, 25]. There were no other significant differences in other adverse events or clinic visits. Administration of azithromycin to preschool aged children appears to be safe and well tolerated [19, 20].

The implications of utilizing an antibiotic, such as azithromycin, for malaria prophylaxis should be considered. Selection pressure for antimicrobial resistance can arise following over-administering antibiotics. Resistance to antibiotics could render treatment against other bacterial infections ineffective, which is a serious concern for global health [33]. The results of this study do not suggest that the use of azithromycin for prevention or treatment of malaria at the individual level is appropriate, and given concerns for selection for resistance, its use should be avoided.

Limitations for this study include the sole use of an RDT rather than PCR or microscopy for defining malaria positivity. Some trials have documented low RDT sensitivity in this setting with results that may vary by parasite density [34, 35]. RDTs generally perform worse with low parasite density infections, but due to the randomized nature of the study we do not expect any differential bias between study arms [36]. Future studies might consider performing more than one RDT test per individual where PCR capabilities are limited. Other limitations should be taken into consideration. Because the trial was designed and powered for a microbiome primary outcome, the trial was likely underpowered to detect differences for malaria specific outcomes. Azithromycin is rapidly absorbed and has a long half-life, but the 2-week duration of the study may have been too short to demonstrate significant effects [37]. Additionally, we did not collect data regarding which children in the trial specifically received SMC for prevention or artemisinin-based combination therapy for those with a malaria diagnosis. While concomitant SMC distribution may reduce the prevalence of malaria parasitemia and reduce power, due to the randomized nature of the study it would not affect inferences. However, effects may be closer to the null than in the absence of SMC. Lastly, this study took place in a single peri-urban town that may not be generalizable to other communities. Nouna Town residents have access to health clinics and may have better health outcomes compared to more rural communities with different malaria transmission patterns. Future research should aim to select a larger number of communities that are not exclusively urban areas.


Azithromycin did not lower malaria positivity as measured by RDT within a 14-day period when administered as a single dose to children 1–59 months old. The point prevalence of fever was similar between the azithromycin and placebo groups, but caregiver-reported fever over the 14-day period from treatment occurred less often among children receiving azithromycin compared to placebo. We found no evidence that individual-level treatment with azithromycin affected malaria prevalence 2 weeks after treatment.

Availability of data and materials

All data is publicly available on OSF (







Centre de Recherche en Santé de Nouna


Confidence interval


Health and Demographic Surveillance System


Mass Drug Administration


Odds ratio


Seasonal malaria chemoprevention




Rapid diagnostic test


United States of America


  1. World Health Organ. WHO World malaria report 2020. Malaria report 2020. Geneva: World Health Organ; 2020. p. 2020.

    Google Scholar 

  2. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Armstrong Schellenberg JRM, Stein C, et al. The burden of malaria mortality among African children in the year 2000. Int J Epidemiol. 2006;35:691–704.

    Article  Google Scholar 

  3. Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, et al. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet. 2020;396:1829–40.

    Article  Google Scholar 

  4. Witkowski B, Berry A, Benoit-Vical F. Resistance to antimalarial compounds: methods and applications. Drug Resist Update. 2009;12:42–50.

    CAS  Article  Google Scholar 

  5. Burns AL, Sleebs BE, Siddiqui G, De Paoli AE, Anderson D, Liffner B, et al. Retargeting azithromycin analogues to have dual-modality antimalarial activity. BMC Biol. 2020;18(1):133.

    CAS  Article  Google Scholar 

  6. Oldenburg CE, Amza A, Cooley G, Kadri B, Nassirou B, Arnold BF, et al. Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: a sub-study of a cluster randomized trial. Malar J. 2019;18:389.

    CAS  Article  Google Scholar 

  7. Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, et al. Azithromycin to reduce childhood mortality in Sub-Saharan Africa. N Engl J Med. 2018;378:1583.

    CAS  Article  Google Scholar 

  8. Arzika AM, Maliki R, Boubacar N, Kane S, Cotter SY, Lebas E, et al. Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: a cluster-randomized, placebo-controlled trial. PLoS Med. 2019;16:e1002835.

    Article  Google Scholar 

  9. FY 2020 Burkina Faso Malaria Operational Plan. Accessed 13 May 2021.

  10. De M, Sante LA, Faso B. Avec l’appui de l’UNICEF.

  11. Hammer GP, Somé F, Müller O, Kynast-Wolf G, Kouyaté B, Becher H. Pattern of cause-specific childhood mortality in a malaria endemic area of Burkina Faso. Malar J. 2006;5(1):1–8.

    Article  Google Scholar 

  12. Nouna HDSS, Burkina Faso brief description of Nouna HDSS.

  13. Mank I, Belesova K, Bliefernicht J, Traoré I, Wilkinson P, Danquah I, et al. The impact of rainfall variability on diets and undernutrition of young children in rural Burkina Faso. Front Public Health. 2021;0:1376.

    Google Scholar 

  14. Sié A, Louis V, Gbangou A, Müller O, Niamba L, Stieglbauer G, et al. The health and demographic surveillance system (HDSS) in Nouna, Burkina Faso, 1993–2007. Glob Health Action. 2010;3:5284.

    Article  Google Scholar 

  15. Otte Im Kampe E, Müller O, Sie A, Becher H. Seasonal and temporal trends in all-cause and malaria mortality in rural Burkina Faso, 1998–2007. Malar J. 2015;14:300.

    Article  Google Scholar 

  16. States Agency for International Development U. PMI VECTORLINK Burkina Faso entomological monitoring annual report, January—December 2019. 2019.

  17. Tourre YM, Vignolles C, Viel C, Faruque FS, Malone JB. Malaria in Burkina Faso (West Africa) during the twenty-first century.

  18. Basilion EV, Kilima PM, Mecaskey JW. Simplification and improvement of height-based azithromycin treatment for paediatric trachoma. Trans R Soc Trop Med Hyg. 2005;99:6–12.

    CAS  Article  Google Scholar 

  19. Sié A, Dah C, Bountogo M, Ouattara M, Nebie E, Coulibaly B, et al. Adverse events and clinic visits following a single dose of oral azithromycin among preschool children: a randomized placebo-controlled trial. Am J Trop Med Hyg. 2021;104:1137–41.

    Google Scholar 

  20. Oldenburg CE, Arzika AM, Maliki R, Kane MS, Lebas E, Ray KJ, et al. Safety of azithromycin in infants under six months of age in Niger: a community randomized trial. PLoS Negl Trop Dis. 2018;12(11):e0006950.

    CAS  Article  Google Scholar 

  21. Ayele B, Gebre T, House JI, Zhou Z, McCulloch CE, Porco TC, et al. Adverse events after mass azithromycin treatments for trachoma in Ethiopia. Am J Trop Med Hyg. 2011;85(2):291–4.

    Article  Google Scholar 

  22. Phiri MD, Cairns M, Zongo I, Nikiema F, Diarra M, Yerbanga RS, et al. The duration of protection from azithromycin against malaria, acute respiratory, gastrointestinal, and skin infections when given alongside seasonal malaria chemoprevention: secondary analyses of data from a clinical trial in Houndé, Burkina Faso, and Bou. Clin Infect Dis. 2021;73:e2379–86.

    CAS  Article  Google Scholar 

  23. WHO. Burkina Faso world malaria report. 2016. Accessed 14 May 2021.

  24. Schachterle SE, Mtove G, Levens JP, Clemens E, Shi L, Raj A, et al. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania. Emerg Infect Dis. 2014;20:941–9.

    CAS  Article  Google Scholar 

  25. Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, et al. Effect of adding azithromycin to seasonal malaria chemoprevention. N Engl J Med. 2019;380:2197–206.

    Article  Google Scholar 

  26. Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An epidemiological study to assess Plasmodium falciparum parasite prevalence and malaria control measures in Burkina Faso and Senegal. Malar J. 2017;16:63.

    Article  Google Scholar 

  27. Gaynor BD, Amza A, Kadri B, Nassirou B, Lawan O, Maman L, et al. Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: A cluster-randomized trial. Am J Trop Med Hyg. 2014;90(5):846–51.

    CAS  Article  Google Scholar 

  28. Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA J Am Med Assoc. 2009;302(9):962–8.

    CAS  Article  Google Scholar 

  29. O’Brien KS, Cotter SY, Amza A, Kadri B, Nassirou B, Stoller NE, et al. Mass azithromycin and malaria parasitemia in Niger: results from a community-randomized trial. Am J Trop Med Hyg. 2017;97(3):696–701.

    Article  Google Scholar 

  30. Bloch EM, Munoz B, Mrango Z, Weaver J, Mboera LEG, Lietman TM, et al. The impact on malaria of biannual treatment with azithromycin in children age less than 5 years: a prospective study. Malar J. 2019;18(1):284.

    Article  Google Scholar 

  31. Hart JD, Samikwa L, Sikina F, Kalua K, Keenan JD, Lietman TM, et al. Effects of biannual azithromycin mass drug administration on malaria in Malawian children: a cluster-randomized trial. Am J Trop Med Hyg. 2020;103(3):1329–34.

    Article  Google Scholar 

  32. Gendrin M, Yerbanga RS, Ouedraogo JB, Lefèvre T, Cohuet A, Christophides GK. Differential effects of azithromycin, doxycycline, and cotrimoxazole in ingested blood on the vectorial capacity of malaria mosquitoes. Open Forum Infect Dis. 2016;3:ofw074.

    Article  Google Scholar 

  33. World Health Organ. Antimicrobial resistance. Global report on surveillance. Geneva: World Health Organ; 2014.

    Google Scholar 

  34. Tiono AB, Ouédraogo A, Diarra A, Coulibaly S, Soulama I, Konaté AT, et al. Lessons learned from the use of HRP-2 based rapid diagnostic test in community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J. 2014;13:30.

    Article  Google Scholar 

  35. Watson OJ, Sumner KM, Janko M, Goel V, Winskill P, Slater HC, et al. False-negative malaria rapid diagnostic test results and their impact on community-based malaria surveys in sub-Saharan Africa. BMJ Glob Health. 2019;4:e001582.

    Article  Google Scholar 

  36. Plucinski MM, Dimbu PR, Fortes F, Murphy SC, Smith NT, Cruz KR, et al. Malaria parasite density in individuals with different rapid diagnostic test results and concentrations of HRP2 antigen. Am J Trop Med Hyg. 2019;100:1202–3.

    CAS  Article  Google Scholar 

  37. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. Ann Pharmacother. 1998;32:785–93.

    CAS  Article  Google Scholar 

Download references


We gratefully acknowledge the participants and caregivers as well as research staff involved in data collection.


This work was supported by the Bill and Melinda Gates Foundation (OPP1187628). Azithromycin and matching placebo were donated by Pfizer, Inc. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations



AS, CEO, and TL conceptualized and designed the trial. CD, MB, BC, MO, GC, EN, MS, and IK led the data collection with support from JB, EL, BA, and CEO. IK led the data management for the project with support from FN, HH, and BA. JB and CEO conducted the analyses, created the tables, and wrote the first draft of the manuscript. All authors contributed to the implementation of the study, interpretation, final revisions to the text. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Catherine E. Oldenburg.

Ethics declarations

Ethics approval and consent to participate

The study was reviewed by the Institutional Review Boards at the University of California, San Francisco and the National Ethics Committee of Burkina Faso. Written informed consent was obtained from the caregivers of all participants. All methods were carried out in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

No conflicts of interest are reported. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brogdon, J., Dah, C., Sié, A. et al. Malaria positivity following a single oral dose of azithromycin among children in Burkina Faso: a randomized controlled trial. BMC Infect Dis 22, 285 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Azithromycin
  • Sahel
  • Malaria
  • Randomized controlled trial